In vitro diagnostic (IVD) kits have been widely applied in disease diagnosis, prognosis, and therapeutic monitoring. With rich and vast experience in antibody development, Creative Biolabs has launched a whole series of biomarker-specific IVD antibody development services. Here, we focus on CCND3 as a marker of ovarian cancer and chronic myeloid leukemia.
The Overview of Cyclin D3 (CCND3)
Encoded by CCND3 gene, CCND3 protein belongs to the highly conserved cyclin family. All the cyclin members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins act as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns. Different expressions contribute to the temporal coordination of each mitotic event. CCND3 forms a complex with CDK4 or CDK6, and functions as a regulatory subunit of those two proteins. A number of reports have revealed that CCND3 are involved in the phosphorylation of tumor suppressor protein Rb. The CDK4 activity associated with CCND3 was reported to be necessary for cell cycle progression through G2 phase into mitosis after UV radiation. Several transcript variants of CCND3 have been found so far.
Figure 1 Cyclin D3 immunostaining in breast cancer (Yayun Chi., 2015)
CCND3 Marker of Tumor Cells
CDKs promote cell cycle transitions in mammalian cells by phosphorylating key substrates cyclins. Abnormal expression of cyclins was reported to be involved in many cancers progression. Highly expression of Cyclin D3 was reported in a number of tumor cells. Cyclin D3 gene is amplified in bladder carcinoma in situ. Genomic changes disrupting the expression of Cyclin D3 are involved in the aberrant growth of several human B-lymphoid malignancies. Targeting Cyclin D3 by miR-138 induces cell cycle arrest in hepatocellular carcinoma. Furthermore, Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. For breast cancer, CCND3 is overexpressed in human breast cancer cell lines and primary invasive breast cancers. In addition, E1AF promotes breast cancer cell cycle progression via upregulation of CCND3 transcription. All the studies reveal that CCND3 is the marker of many tumor cells.
IVD antibodies are extensively used in immunodiagnostic kits for disease screening, prognosis, and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop novel CCND3-specific antibodies for diagnostic uses. With our versatile IVD platform, we also offer immunoassay development services from scratch to commercial IVD kits. We can start with antigen sequences or available antibody pairs.
For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
For Research Use Only.
